JNK2 Protein (AA 101-424) (His tag)

Catalog No. ABIN7505293

Product Details

Target: JNK2 (MAPK9) (Mitogen-Activated Protein Kinase 9 (MAPK9))

Protein Type: Recombinant

Protein Characteristics: AA 101-424

Origin: Human

Source: Escherichia coli (E. coli)

Purification tag / Conjugate: This JNK2 protein is labelled with His tag.

Sequence: Phe 101-Arg 424

Characteristics: A DNA sequence encoding the Human MAPK9 protein (P45984) (Phe 101-Arg 424) was expressed with a N-His&C-His tag.

Purity: > 95 % as determined by reducing SDS-PAGE.

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: Lyophilized from sterile PBS, pH 7.4.
Normally 5 % - 8 % trehalose, mannitol and 0.01 % Tween80 are added as protectants before lyophilization.

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Expiry Date: 12 months

Target Details

Target: JNK2 (MAPK9) (Mitogen-Activated Protein Kinase 9 (MAPK9))

Alternative Name: MAPK9 (MAPK9 Products)

Synonyms: MAPK9 Protein, JNK-55 Protein, JNK2 Protein, JNK2A Protein, JNK2ALPHA Protein, JNK2B Protein, JNK2BETA Protein, PRKM9 Protein, SAPK Protein, SAPK1a Protein, p54a Protein, p54aSAPK Protein, AI851083 Protein, Prkm9 Protein, JNK2-ALPHA1 Protein, MAP kinase 9 Protein, mitogen-activated protein kinase 9 Protein, MAP kinase 9 Protein, MAPK9 Protein, Mapk9 Protein, MPK9 Protein

Background:

Abbreviation: MAPK9

Target Synonym: JNK-55,JNK2,JNK2A,JNK2ALPHA,JNK2B,JNK2BETA,p54a,p54aSAPK,PRKM9,SAPK,SAPK1a

Background: Mitogen-activated protein kinase 9 (MAPK9), also well known as c-Jun N-terminal kinase (JNK2), is a member of MAP kinase subfamily belonging to the protein kinase superfamily. The crystal structure of human JNK2 complexed with an indazole inhibitor by applying a high-throughput protein engineering and surface-site mutagenesis approach. A novel conformation of the activation loop is observed, which is not compatible with its phosphorylation by upstream kinases. This activation inhibitory conformation of JNK2 is stabilized by the MAP kinase insert that interacts with the activation loop in an induced-fit manner. It suggest that the MAP kinase insert of JNK2 plays a role in the regulation of JNK2 activation, possibly by interacting with intracellular binding partners. JNK2 deficiency leads to reduced c-Jun degradation, thereby augmenting c-Jun levels and cellular proliferation, and suggests that JNK2 is a negative regulator of cellular proliferation in multiple cell types. JNK2 blocks the ubiquitination of tumor suppressor p53, and thus increases the stability of p53 in nonstressed cells. JNK2 negatively regulates antigen-specific CD8+ T cell expansion and effector function, and thus selectively blocking JNK2 in CD8+ T cells may potentially enhance anti-tumor immune response. Lack of JNK2 expression was associated with higher tumor aneuploidy and reduced DNA damage response. Additionally,the JNK2 protein could be a novel therapeutic target in dry eye disease, and may provide a novel target for prevention of vascular disease and atherosclerosis.

Molecular Weight:

Calculated MW: 35.53 kDa

Observed MW: 41 kDa

UniProt: P45984

Pathways: MAPK Signaling, WNT Signaling, TLR Signaling, Fc-epsilon Receptor Signaling Pathway, Activation of Innate immune Response, Cellular Response to Molecule of Bacterial Origin, Positive Regulation of Endopeptidase Activity, Hepatitis C, Toll-Like Receptors Cascades, BCR Signaling, S100 Proteins